Sustained High Level of Serum VEGF at Convalescent Stage Contributes to the Renal Recovery after HTNV Infection in Patients with Hemorrhagic Fever with Renal Syndrome
Table 1
Characteristics of the HFRS patients with different severities.
HFRS severity
Patient number
Male (%)
Mean age (years)
Mean level of maximum blood urea (mmol/L)a
Mean level of maximum serum creatinine (mol/L)a
Mean level of maximum leukocyte (*1000/L)a
Mean level of nadir platelet (*1000/L)a
Mean level of nadir serum albumin (g/L)a
Mean level of maximum atypical lymphocyte (%)b
Mean level of serum maximum VEGF (pg/mL)c
Mean level of serum VEGF at convalescence (pg/mL)
Mild
13
69.2
42.1 (29.8–54.5)
11.8 (6.5–17.2)
194.6 (101.6–287.5)
15.2 (11.1–19.3)
54.8 (35.0–74.6)
34.2 (31.4–37.0)
12.4 (7.6–17.3)
564.9 (487.9–641.9)
193.3 (67.9–454.5)
Moderate
21
71.4
42.9 (34.8–51.1)
15.2 (10.5–20.0)
245.6 (158.6–332.6)
19.6 (13.5–25.7)
44.4 (29.7–59.1)
30.4 (28.3–32.5)
10.4 (8.5–12.3)
603.1 (369.9–836.3)
429.8 (198.2–661.5)
Severe
26
53.8
40.7 (32.9–48.5)
21.7 (16.1–27.3)
403.5 (250.4–556.7)
20.0 (14.5–25.4)
21.1 (10.7–31.6)
28.3 (26.0–30.7)
11.3 (8.3–14.3)
603.8 (398.0–809.5)
494.3 (398.8–589.9)
Critical
28
60.7
46.4 (38.5–54.2)
32.2 (27.4–37.1)
637.7 (544.6–730.8)
35.5 (21.5–49.6)
14.2 (8.3–20.1)
24.0 (21.4–26.5)
12.5 (9.6–15.4)
612.5 (516.4–708.5)
765.7 (429.3–1102.2)*
aThe clinical parameters were statistically analyzed with the maximum or minimal records of each parameter during the course of the disease. The data were presented as mean (95% confidence interval).
bThe atypical lymphocyte morphology was defined as either prolymphocytes or lymphocytes with cleaved nuclei or lymphoplasmacytoid cells by microscope. The data were presented as mean (95% confidence interval).
cVEGF: vascular endothelial growth factor. The level of serum VEGF was statistically analyzed with the maximum value of each patient during the hospitalization. There was no difference between the four different severity groups, .
*There was significant difference of serum VEGF level between the critical group and other group (mild, moderate, or severe) at convalescence stage of the disease, .
